Avandia
A public safety advisory was issued in 2007 to warn Avandia patients of the cardiovascular risk associated with the drug's use. However, the FDA has not issued an Avandia recall, claiming that sufficient evidence as to the dangers versus the benefits of the the drug does not exist. Currently, Avandia's manufacturer and other researchers are conducting additional studies to determine the safety level of Avandia. In the meantime, patients across the United States have experienced adverse medical events related to the use of the drug and many have filed Avandia lawsuits.
On this website LegalView provides numerous resources on Avandia. Follow this link to learn more about Avandia. If you are seeking Avandia legal assistance, please fill out a contact form at any time. When you submit a contact form, a qualified Avandia lawyer will receive your information and contact you.
Avandia Case Evaluation Form
| Name: | Avandia | |
| Generic: | Rosiglitazone |
Hyperglycaemia - A typical condition associated with diabetes mellitus. It occurs when levels of glucose are elevated in the blood. There are no obvious effects, but the condition can lead to many long-term complications. See our Avandia Glossary |
| Manufacturer: | GlaxoSmithKlein | |
| Date approved: | May 25, 1999 | |
| Status: | Prescription only | |
| Approved uses: | Treatment of diabetes | |
| Off-Label uses: | Possible benefit to some sufferers of Alzheimer's disease. | |
| Side effects: |
|
|
| Related topics: | Avandaryl, Unsafe Drugs | |
Avandia
Avandia, or rosiglitazone, is a thiazolidinedione anti-diabetic drug manufactured by GlaxoSmithKlein. It is primarily used in the treatment of type 2 diabetes mellitus. Side effects include a possible increased incidence of minor bone fractures. Recently, drugs containing such as Avandia that contain rosiglitazone have been linked to significantly increased risk of heart attack and other ischemic cardiac events. While increased risk of heart attack is currently listed as a warning on the Avandia label, the FDA is evaluating a number of clinical studies to determine the clinical significance of that risk and what, if any action should be taken.






